Search

Coloplast A-S (Class B)

Fermé

569.8 -0.9

Résumé

Variation du prix de l'action

24h

Actuel

Min

564.4

Max

579.4

Chiffres clés

By Trading Economics

Revenu

70M

875M

Ventes

2M

7B

P/E

Moyenne du Secteur

35.807

90.831

BPA

3.88

Rendement du dividende

4.01

Marge bénéficiaire

12.572

Employés

16,744

EBITDA

2B

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+11.86% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

4.01%

2.20%

Prochains Résultats

6 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

7.5B

130B

Ouverture précédente

570.7

Clôture précédente

569.8

Coloplast A-S (Class B) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

14 janv. 2026, 22:41 UTC

Acquisitions, Fusions, Rachats

Canadian Natural Resources, Tourmaline File Deal Notice With Antitrust Regulator

15 janv. 2026, 00:00 UTC

Résultats

Welcome to Greenland, an Economy Reliant on Subsidies and Shrimp -- WSJ

14 janv. 2026, 23:47 UTC

Market Talk

Oil Slips After Trump Appears to Tilt Away From Military Action in Iran -- Market Talk

14 janv. 2026, 23:44 UTC

Market Talk

Nikkei May Decline After Hitting Record Highs; Election in Focus -- Market Talk

14 janv. 2026, 23:39 UTC

Market Talk

ANZ's New Bull Still Sees Valuation Gap to Peers -- Market Talk

14 janv. 2026, 23:32 UTC

Market Talk

Gold Declines on Likely Technical Correction, Possible Profit-Taking -- Market Talk

14 janv. 2026, 22:56 UTC

Acquisitions, Fusions, Rachats

Soho House Amends Rollover and Support Agreements With Broad Street Principal Investments and Others

14 janv. 2026, 22:53 UTC

Acquisitions, Fusions, Rachats

Soho House: Apollo Global Management and Goldman Sachs Asset Management Amend Debt Commitment

14 janv. 2026, 22:17 UTC

Market Talk

Global Equities Roundup: Market Talk

14 janv. 2026, 22:17 UTC

Market Talk

WiseTech's Revenue Growth Drivers Attract Scrutiny -- Market Talk

14 janv. 2026, 22:09 UTC

Résultats

CITIC Securities: Uptrend in China Capital Markets Supported Results >600030.SH

14 janv. 2026, 22:08 UTC

Résultats

CITIC Securities 2025 Oper Rev CNY74.83B Vs. CNY58.12B >600030.SH

14 janv. 2026, 22:08 UTC

Résultats

CITIC Securities 2025 Net CNY30.05B Vs. Net CNY21.57B >600030.SH

14 janv. 2026, 21:53 UTC

Acquisitions, Fusions, Rachats

WuXi XDC Expects 2025 Net to Increase Over 38% on Year

14 janv. 2026, 21:53 UTC

Acquisitions, Fusions, Rachats

WuXi XDC Expects 2025 Revenue to Increase More Than 45% on Year

14 janv. 2026, 21:52 UTC

Acquisitions, Fusions, Rachats

WuXi XDC Announces Positive Profit Alert for 2025

14 janv. 2026, 21:51 UTC

Acquisitions, Fusions, Rachats

Citigroup Acting as Financial Advisor to WuXi XDC

14 janv. 2026, 21:51 UTC

Acquisitions, Fusions, Rachats

WuXi XDC: Aims to Keep Listing Status of BioDlink

14 janv. 2026, 21:51 UTC

Acquisitions, Fusions, Rachats

WuXi XDC: Company to Finance BioDlink Shares Acquisition via Internal Resources

14 janv. 2026, 21:50 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

14 janv. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

14 janv. 2026, 21:49 UTC

Acquisitions, Fusions, Rachats

WuXi XDC: BioDlink Offer to Cost HK$2.79B

14 janv. 2026, 21:48 UTC

Acquisitions, Fusions, Rachats

WuXi XDC Offers to Pay HK$4.00 for Each BioDlink International Share

14 janv. 2026, 21:48 UTC

Acquisitions, Fusions, Rachats

WuXi XDC Makes Cash Offer for BioDlink International

14 janv. 2026, 21:13 UTC

Market Talk

Oil Retreats Late After Trump Comments on Iran -- Market Talk

14 janv. 2026, 20:30 UTC

Market Talk
Résultats

Danaher's Preliminary 4Q Seen as Promising -- Market Talk

14 janv. 2026, 20:13 UTC

Market Talk

U.S. Natural Gas Futures Sink Ahead of Storage Report -- Market Talk

14 janv. 2026, 20:08 UTC

Market Talk

Oil Futures Extend Rally on Iran Tensions -- Market Talk

14 janv. 2026, 19:33 UTC

Market Talk

Nutrien Seen as Winner in Tighter 2026 Potash Market, Higher Prices -- Market Talk

14 janv. 2026, 19:06 UTC

Market Talk
Résultats

Wells Fargo Says Customers, Economy Remain Resilient -- Market Talk

Coloplast A-S (Class B) prévision

Objectif de Prix

By TipRanks

11.86% hausse

Prévisions sur 12 Mois

Moyen 901.38 DKK  11.86%

Haut 1,056 DKK

Bas 720 DKK

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

8 ratings

2

Achat

4

Maintien

2

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
help-icon Live chat